WO1997047293B1 - Utilisation de preparations contenant des antagonistes et des agonistes d'opiate pour assurer la prohylaxie et le traitement therapeutique de migraines - Google Patents
Utilisation de preparations contenant des antagonistes et des agonistes d'opiate pour assurer la prohylaxie et le traitement therapeutique de migrainesInfo
- Publication number
- WO1997047293B1 WO1997047293B1 PCT/EP1997/002823 EP9702823W WO9747293B1 WO 1997047293 B1 WO1997047293 B1 WO 1997047293B1 EP 9702823 W EP9702823 W EP 9702823W WO 9747293 B1 WO9747293 B1 WO 9747293B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- opiate receptor
- pharmaceutical preparations
- receptor antagonist
- preparations according
- containing pharmaceutical
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract 5
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 3
- 238000011282 treatment Methods 0.000 title claims abstract 3
- 239000003401 opiate antagonist Substances 0.000 title claims 6
- 238000002360 preparation method Methods 0.000 title claims 3
- 239000003402 opiate agonist Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 claims abstract 3
- 102000003840 Opioid Receptors Human genes 0.000 claims abstract 2
- 108090000137 Opioid Receptors Proteins 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 3
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 229960002921 methylnaltrexone Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- SPPAUICKSNQRNC-GNUVVZJLSA-N (4r,4as,7r,7ar,12bs)-7-amino-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N)CN2CC1CC1 SPPAUICKSNQRNC-GNUVVZJLSA-N 0.000 claims 1
- WXOUFNFMPVMGFZ-BDQAUFNLSA-N 7-Benzylidenenaltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC(/C5=O)=C\C=2C=CC=CC=2)O)CC1)O)CC1CC1 WXOUFNFMPVMGFZ-BDQAUFNLSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical class C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Abstract
L'invention concerne l'utilisation de composés ayant des effets antagonistes et/ou agonistes sur le récepteur d'opiate, pour assurer la prophylaxie ou la prévention, et pour traiter thérapeutiquement des maux de tête aigus ou chroniques associés à la migraine ou à des affections apparentées à la migraine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU30310/97A AU3031097A (en) | 1996-06-07 | 1997-05-30 | Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19622866A DE19622866C2 (de) | 1996-06-07 | 1996-06-07 | Verwendung von Opiat-Antagonisten und -Agonisten enthaltende Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen |
| DE19622866.2 | 1996-06-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997047293A1 WO1997047293A1 (fr) | 1997-12-18 |
| WO1997047293B1 true WO1997047293B1 (fr) | 1998-01-29 |
Family
ID=7796378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/002823 WO1997047293A1 (fr) | 1996-06-07 | 1997-05-30 | Utilisation de preparations contenant des antagonistes et des agonistes d'opiate pour assurer la prohylaxie et le traitement therapeutique de migraines |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3031097A (fr) |
| DE (1) | DE19622866C2 (fr) |
| WO (1) | WO1997047293A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| US6096738A (en) * | 1999-01-28 | 2000-08-01 | Winston Laboratories, Inc. | Method for treatment of headache |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU224914B1 (en) * | 1994-05-31 | 2006-04-28 | Mallinckrodt Chemical Inc | Process for the preparation of nalbuphine having not more then 1% levels of beta-epimer |
-
1996
- 1996-06-07 DE DE19622866A patent/DE19622866C2/de not_active Expired - Fee Related
-
1997
- 1997-05-30 AU AU30310/97A patent/AU3031097A/en not_active Abandoned
- 1997-05-30 WO PCT/EP1997/002823 patent/WO1997047293A1/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kulkarni | Heat and other physiological stress-induced analgesia: catecholamine mediated and naloxone reversible response | |
| DE60219478T2 (de) | Orale gabe von 6-hydroxy-oxymorphon als analgetikum | |
| DE4325465B4 (de) | Orales pharmazeutisches Präparat für die Schmerztherapie | |
| DE69214230T2 (de) | Codeinonderivate und ihre pharmazeutische Verwendung | |
| CA2379524A1 (fr) | Sels et bases de la molecule de 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol destines a optimiser l'homeostase de la dopamine pendant l'administration d'analgesiques opioides | |
| KR19990067527A (ko) | 동통의 치료를 위한 에피나스틴의 용도 | |
| KR970009799A (ko) | 물질 남용 금단의 치료 방법 | |
| US4379789A (en) | Analgesic composition | |
| EP1456212A1 (fr) | Derives de 6-aminomorphinane, leur procede de production et leur utilisation | |
| JP2003520234A (ja) | 薬物中毒の治療方法 | |
| WO2012062676A1 (fr) | Lisuride, terguride et leurs dérivés pour une utilisation dans la prophylaxie et/ou la thérapie de modifications fibreuses | |
| US20070299098A1 (en) | Therapeutic Agent for Neuropathic Pain | |
| DE102007018150A1 (de) | VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz | |
| DE69209140T2 (de) | Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen | |
| DE3415394A1 (de) | Medikament gegen ovarialinsuffizienz | |
| WO1997047293B1 (fr) | Utilisation de preparations contenant des antagonistes et des agonistes d'opiate pour assurer la prohylaxie et le traitement therapeutique de migraines | |
| US4898860A (en) | Anticonvulsant composition and method | |
| US20100075992A1 (en) | Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain | |
| DE69522764T2 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| DE69814089T2 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung | |
| US20190209540A1 (en) | Sublingual opioid formulations containing naloxone | |
| DE3525390C2 (fr) | ||
| DE19622866C2 (de) | Verwendung von Opiat-Antagonisten und -Agonisten enthaltende Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen | |
| WO1993002707A1 (fr) | Anti-diarrheiques nouveaux | |
| DE102006015734A1 (de) | Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung |